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Lars	Rebien	Sørensen:	It	makes	no	sense	for
countries	to	develop	vaccines	individually
Although	it	can	be	difficult	to	predict	exactly	how	the	next	health	crisis	will	impact	us,	there	are	valuable	lessons	to
be	learned	from	the	current	one.	Lessons	which	should	be	brought	to	the	table	in	future	political	discussions	across
the	world.	Because	it	is	clear	that	politicians	and	other	decision-makers	now	look	at	our	preparedness	and
response	systems	with	newfound	attention	compared	to	just	a	few	months	ago.
The	ongoing	crisis	has	opened	our	eyes	in	two	areas	especially,	namely	testing	of	diseases	and	the	development	of
vaccines.
As	for	testing	of	diseases,	many	of	us	were	inadequately	prepared.	Many	countries	could	have	avoided	the
widescale	shutdown	of	society	we	have	seen	if	the	necessary	capacities	for	testing	and	putting	potential	carriers
into	quarantine	had	been	in	place.
The	shortage	of	test	kits	and	the	need	for	increased	test	capacities	are	challenges	that	are	already	being
addressed.	We	have	been	building	the	road	as	we	are	driving	on	it,	and	in	the	coming	months,	we	will	see	testing	of
people	being	ramped	up	in	many	countries.
“I	shake	my	head	in	disbelief	when	I	hear	politicians
argue	that	we	need	vaccine	production	at	the	national
level.”
Our	current	experiences	with	capacity	building	and	organisation	of	testing	is	something	we	can	learn	from,	so	as	to
be	better	prepared	in	connection	with	the	next	health	crisis.	Having	massive	stockpiles	of	test	kits	for	all	sorts	of
viruses	is	not	a	viable	solution,	as	every	virus	differs	and	tests	must	be	tailored	to	the	specific	situation.	Instead,	we
should	consider	building	a	flexible	preparedness	and	response	system	which	can	be	upscaled	at	short	notice	when
the	need	arises.	Collaborating	at	a	European	level	in	this	regard	would	be	an	obvious	idea.
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The	COVID-19	crisis	has	also	helped	us	to	recognise	that	security	of	supply	in	relation	to	vaccines	constitutes	a
critical	infrastructure.	Until	now,	developing	vaccines	for	viral	epidemics	has	not	been	good	business	for
pharmaceutical	companies.	In	most	cases,	epidemics	are	contained	before	a	safe	vaccine	can	be	ready	for	market.
Moreover,	there	is	an	issue	with	the	incentive	structure	for	a	vaccine	that	the	entire	world	needs	access	to	and
which	should	be	as	inexpensive	as	possible.	What	is	the	incentive	to	develop	it?
The	business	model	for	vaccines	can	be	compared	to	that	for	antibiotics.	The	EU	has	already	taken	steps	to	focus
on	the	development	of	new	antibiotics,	as	production	on	market	terms	is	not	viable.	Antibiotic	resistance	is	an
example	of	an	already	recognised	global	health	crisis	which	can	only	be	solved	through	international	cooperation.
In	many	countries	there	is	a	debate	on	how	to	become	self-sufficient	in	the	area	of	vaccines,	but	the	answer	is
clear:	It	is	not	possible.	The	thought	is	appealing,	no	doubt,	but	we	live	in	a	globalised	world,	which	means	that
diseases	spread	more	rapidly	than	we	can	prevent	them.	And	in	a	world	with	extensive	trade	across	borders,	we
are	all	part	of	the	solution.
I	shake	my	head	in	disbelief	when	I	hear	politicians	argue	that	we	need	vaccine	production	at	the	national	level.	It
would	be	unwise	to	go	down	that	road.	It	makes	no	sense	to	let	the	countries	develop	vaccines	individually,	when
we	have	an	opportunity	to	pool	together	and	utilise	a	global	capacity	of	researchers	and	the	economic	foundation
behind	their	work.	This	type	of	production	should	take	place	in	a	public-private	partnership	and	would	be	best
served	in	a	European	or	–	as	has	been	the	case	so	far	–	international	framework.
One	of	the	problems	of	developing	new	vaccines	is	that	we	do	not	know	which	one	will	prove	most	effective.	In	fact,
we	may	end	up	with	more	than	one	type	of	vaccine,	e.g.	one	for	prevention	and	another	for	the	seriously	ill.	Every
vaccine	relies	on	its	own	technology,	and	according	to	the	WHO,	there	are	currently	well	above	100	vaccine
projects	in	progress.
In	addition	to	this,	medical	production	is	subject	to	strict	safety	requirements	which	will	be	difficult	to	uphold	in	a
vaccine-manufacturing	facility	that	does	not	run	continuously	at	full	capacity.	In	Denmark,	for	instance,	setting	up
such	a	production	would	be	hopeless:	It	would	remain	at	a	standstill	most	of	the	time,	leaving	us	with	over-capacity
in	an	industry	that	in	the	long	term	would	not	be	cost-effective.
At	the	European	level,	we	need	to	come	up	with	common	solutions	for	all	the	countries	which	may	ensure	a	fast-
track	approach	to	developing	vaccines	during	crises.	The	Covid-19	crisis	transcends	national	boundaries,	so	will	the
next	health	crisis	and	so	should	the	efforts	on	prevention,	treatment	and	developing	vaccines.	It	is	only	through	a
European	collaboration	between	public	and	private	actors	that	we	will	be	able	to	achieve	an	adequate	test	capacity
for	various	types	of	viruses	and	a	fast	development	of	vaccines	that	can	then	be	produced	in	sufficient	numbers.
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Notes:
Lars	Rebien	Sørensen	took	part	in	a	recent	meeting	of	the	World	Economic	Forum’s	COVID	Action	Platform
for	Media.
The	post	expresses	the	views	of	its	author(s),	not	the	position	of	LSE	Business	Review	or	the	London	School
of	Economics.
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Lars	Rebien	Sørensen	is	chairman	of	the	board	of	directors	of	the	Novo	Nordisk	Foundation.	He
was	CEO	of	the	Danish	pharmaceutical	company	Novo	Nordisk	from	2000	to	2017.
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